tyrosinekinases

Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.

Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC₅₀=3.3/2.8 nM) that is potent and selective. Rixolitinib exhibits antitumor activity and induces autophagy and apoptosis.

Deucravacitinib is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12/23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC₅₀ of 1.0 nM.

Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC₅₀: 0.5 nM) that selectively blocks B cell activation.

Lorlatinib (PF-6463922) is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity.

Hypericin (Cyclosan) is a natural anthraquinone compound, an extract of Hypericum perforatum, which inhibits PKC, MAO, dopamine-beta-hydroxylase, reverse transcriptase, telomerase, and CYP, etc. Hypericin exhibits antimicrobial, antiviral, antitumor, and antidepressant activities.

Tafetinib (SIM-010603) is a novel potent and orally available tyrosine kinase inhibitor with anti-angiogenic and anti-tumour activity.

NVP-BSK805 2HCl (1092499-93-8(free base)) (BSK 805)(IC₅₀=0.5 nM), a specific and effective ATP-competitive JAK2 inhibitor, is more than 20-fold specificity over JAK1, JAK3 and TYK2.

Vamotinib (PF-114) is an orally active and specific tyrosine kinase inhibitor with antiproliferative and antitumour activity.Vamotinib inhibits the phosphorylation of BCR/ABL and BCR/ABL-T315I, which promotes apoptosis. Vamotinib is used to study drug-resistant Philadelphia chromosome-positive (Ph+) leukaemia and Alzheimer's disease.

Zongertinib (BI 1810631) is a HER2 inhibitor, a selective HER2 tyrosine kinase inhibitor (with IC₅₀ values of 13 nM and 579 nM for HER2 and EGFR, respectively), featuring covalent binding properties, used for solid tumor research.

EGFR-IN-87 is a potent EGFR tyrosine kinase inhibitor with anticancer activity that inhibits EGFR_d746-750, EGFR_L858R/T790M, and EGFR_WT in A431 cells, and can be used for cancer research.

Vidarabine (Adenine Arabinoside) is a nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.

Baricitinib (INCB028050) is a JAK1 and JAK2 inhibitor (IC₅₀=5.9/5.7 nM) with selective and oral activity. Baricitinib has potential anti-inflammatory, immunomodulatory and anti-tumor activity.

Ilginatinib maleate (NS-018 maleate) is a highly active, orally bioavailable inhibitor of JAK2.

RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC₅₀ of 1.5nM as tested in cell-based pharmacological assays

ST271 is an effective protein tyrosine kinase (PTK) inhibitor.

SU 4981 is an inhibitor of VEGFR and a modulator of tyrosine kinase activity.

SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.

Ilginatinib (NS-018) is a highly active, orally bioavailable JAK2 inhibitor.

Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active, orally bioavailable JAK2 inhibitor.

Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC₅₀: 485 nM).

Ropsacitinib (PF-06826647) is a selective TYK2 inhibitor, which binds to TYK2 catalytically active JH1 domain (IC₅₀: 17 nM).

AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC₅₀: 1.6 μM).

BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor with IC₅₀ values of 9 nM and 72 nM, respectively. BMS-066 is used in kinase signaling research systems to investigate NF-κB pathway regulation, JAK/STAT-associated signaling modulation, and inflammatory response control in cellular disease models.